Skip to content

Chapters ENES DE

XExtension Codes
Substances
XM6S30Medicaments
XM6WT8Agents primarily affecting blood constituents or immune system
Antineoplastic agents
XM1JG6Monoclonal antibodies and antibody drug conjugates
XM9ND9Programmed cell death protein 1/death ligand 1 inhibitors

XM0550 category

Amivantamab

Also indexed as

Amivantamab

Nearby in Programmed cell death protein 1/death ligand 1 inhibitors

XM3Q80Tislelizumab
XM2KA7Retifanlimab
XM0AN7Oportuzumab monatox
XM5Q93Sacituzumab govitecan

PreviousXM5Q93 — Sacituzumab govitecan

Browse ICD-11

01Certain infectious or parasitic diseases
02Neoplasms
03Diseases of the blood or blood-forming organs
04Diseases of the immune system
05Endocrine, nutritional or metabolic diseases
06Mental, behavioural or neurodevelopmental disorders
07Sleep-wake disorders
08Diseases of the nervous system
09Diseases of the visual system
10Diseases of the ear or mastoid process
11Diseases of the circulatory system
12Diseases of the respiratory system
13Diseases of the digestive system
14Diseases of the skin
15Diseases of the musculoskeletal system or connective tissue
16Diseases of the genitourinary system
17Conditions related to sexual health
18Pregnancy, childbirth or the puerperium
19Certain conditions originating in the perinatal period
20Developmental anomalies
21Symptoms, signs or clinical findings, not elsewhere classified
22Injury, poisoning or certain other consequences of external causes
23External causes of morbidity or mortality
24Factors influencing health status or contact with health services
25Codes for special purposes
26Supplementary Chapter Traditional Medicine Conditions
VSupplementary section for functioning assessment
XExtension Codes
Histopathology
Dimensions of injury
Dimensions of external causes
Consciousness
Substances
Diagnosis code descriptors
Capacity or context
Health Devices, Equipment and Supplies
Extension codes of particular relevance to skin diseases
5 more
XM6S30Medicaments
XM9N55Substances, chiefly nonmedicinal
Allergens
XM3MU3Agents primarily affecting the gastrointestinal system
XM6WT8Agents primarily affecting blood constituents or immune system
XM3KY1Agents affecting genitourinary system, sex or anabolic hormones
XM26S4Hormones and their synthetic substitutes or antagonists, not elsewhere classified
XM9W63Agents affecting bones, joints or other connective tissue, not elsewhere classified
XM4TG8Agents primarily affecting water and nutrition-balance or metabolism
XM3973Agents primarily affecting the cardiovascular system
XM6CH2Drugs primarily affecting the autonomic nervous system
XM7YD4Drugs used in addictive disorders
14 more
Antineoplastic agents
Immunostimulants
Immunosuppressive agents
Anticoagulants and antithrombotics
Other fibrinolysis-affecting drugs
Anticoagulant antagonists, vitamin K and other coagulants
Natural blood and blood products
Iron and its compounds
Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations
4 more
XM09D9Alkylating agents
Antineoplastic antimetabolites
Antineoplastic natural products and derivatives
XM4DQ7Cytotoxic antibiotics and related substances
Monoclonal antibodies
XM3T47Sensitizers used in photodynamic or radiation therapy
Other antineoplastic drugs
XM1CT6Protein kinase inhibitors
XM1JG6Monoclonal antibodies and antibody drug conjugates
XM6TQ6Clusters of differentiation 20 inhibitors
XM0NB9Clusters of differentiation 22 inhibitors
XM4F67Clusters of differentiation 38 inhibitors
XM6DT1Human epidermal growth factor receptor 2 inhibitors
XM3ZP2Epidermal growth factor receptor inhibitors
XM9ND9Programmed cell death protein 1/death ligand 1 inhibitors
XM1GS6Vascular endothelial growth factor inhibitors
XM4ZA4Other monoclonal antibodies and antibody drug conjugates
XM3Q80Tislelizumab
XM2KA7Retifanlimab
XM0AN7Oportuzumab monatox
XM5Q93Sacituzumab govitecan
XM0550Amivantamab

International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021, https://icd.who.int/browse11. Licensed under Creative Commons Attribution-NoDerivatives 3.0 IGO (CC BY-ND 3.0 IGO).

Release 2026-01. View this entity in the official WHO ICD-11 browser.

This page reproduces WHO classification content for reference. It is not medical advice and must not be used to diagnose or treat. For coding decisions, consult the official release and your national coding guidelines.

About · Data & methodology · Privacy · Contact